

Haematologica  
HAEMATOL/2017/169946  
Version 3

CD36 defines primitive chronic myeloid leukemia cells less responsive to imatinib but vulnerable to antibody based therapeutic targeting

Niklas Landberg, Sofia von Palffy, Maria Askmyr, Henrik Lilljebjörn, Carl Sandén, Marianne Rissler, Satu Mustjoki, Henrik Hjorth-Hansen, Johan Richter, Helena Ågerstam, Marcus Järås, and Thoas Fioretos

Disclosures: Funding. This work was supported by the Swedish Cancer Society, the Swedish Children's Cancer Foundation, the Medical Faculty of Lund University, the Swedish Research Council, and the strategic research program BioCARE, and joint grant to Swiss Cancer Center, Lausanne, CREATE Health Cancer Center, and the Medical faculty of Lund University from Biltema Foundation. S.M. is supported by the Finnish Cancer Institute. Conflicts of Interest. T.F and M.J are co-founders of Cantargia. T.F. has received contract research support from Novartis and Bristol-Myers Squibb (BMS). J.R. is a stockholder in Cantargia. J.R., H.H.H. and S.M. have received honoraria and/or research support from Novartis, BMS, Pfizer and Ariad. The remaining authors declare no conflicts of interest.

Contributions: N.L., S.v.P., S.M., H.H.H., J.R., H.A., M.J., and T.F. contributed to designing the study; N.L., S.v.P., M.A., C.S., and M.R. performed the experiments; N.L., H.L., and T.F. analyzed the data; S.M., H.H.H., J.R. collected patient material and clinical data; N.L., and T.F. wrote the manuscript, all authors contributed with valuable comments.